You just read:

Blueprint Medicines Announces PDUFA Date Extension for New Drug Application of Avapritinib for the Treatment of Adults with Fourth-Line Gastrointestinal Stromal Tumor

News provided by

Blueprint Medicines Corporation

Feb 06, 2020, 08:00 ET